CytomX Therapeutics, Inc. (CTMX) Total liabilities 2016–2025
CytomX Therapeutics, Inc. (CTMX) total liabilities at each fiscal year-end, per SEC filings.
$52.6MFY2025 · since FY2016: $120.6M → $52.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $52.6M | -56.6% |
| FY2024 | $121.0M | -51.5% |
| FY2023 | $249.2M | -28.1% |
| FY2022 | $346.6M | +2.0% |
| FY2021 | $339.9M | -7.3% |
| FY2020 | $366.4M | +26.3% |
| FY2019 | $290.2M | -11.1% |
| FY2018 | $326.2M | -0.5% |
| FY2017 | $327.7M | +171.7% |
| FY2016 | $120.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTMX financial trends
CTMX RevenueCTMX Net incomeCTMX Net marginCTMX Gross profitCTMX Gross marginCTMX Operating incomeCTMX Operating marginCTMX Operating cash flowCTMX Free cash flowCTMX Capital expendituresCTMX Return on equityCTMX Stock buybacksCTMX Dividends paidCTMX Total assetsCTMX Shareholders’ equityCTMX overview →